207 related articles for article (PubMed ID: 20012927)
1. Regulatory requirements for clinical trial and marketing authorisation application for gene therapy medicinal products.
Schüle S; Renner M; Longhurst S; Narayanan G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):30-7. PubMed ID: 20012927
[TBL] [Abstract][Full Text] [Related]
2. CAT--the new committee for advanced therapies at the European Medicines Agency.
Celis P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):9-13. PubMed ID: 20084354
[TBL] [Abstract][Full Text] [Related]
3. Regulatory requirements for clinical trial and marketing authorisation application for cell-based medicinal products.
Salmikangas P; Flory E; Reinhardt J; Hinz T; Maciulaitis R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):24-9. PubMed ID: 19940964
[TBL] [Abstract][Full Text] [Related]
4. Environmental risk assessment for medicinal products containing genetically modified organisms.
Anliker B; Longhurst S; Buchholz CJ
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):52-7. PubMed ID: 19940966
[TBL] [Abstract][Full Text] [Related]
5. [Clinical trials with advanced therapy medicinal products].
Schüssler-Lenz M; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
[TBL] [Abstract][Full Text] [Related]
6. Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union.
Narayanan G; Cossu G; Galli MC; Flory E; Ovelgonne H; Salmikangas P; Schneider CK; Trouvin JH
Hum Gene Ther Clin Dev; 2014 Mar; 25(1):1-6. PubMed ID: 24649836
[TBL] [Abstract][Full Text] [Related]
7. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation].
Buljovčić Z
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536
[TBL] [Abstract][Full Text] [Related]
8. The European hospital exemption clause-new option for gene therapy?
Buchholz CJ; Sanzenbacher R; Schüle S
Hum Gene Ther; 2012 Jan; 23(1):7-12. PubMed ID: 22247961
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany.
Renner M; Anliker B; Sanzenbacher R; Schuele S
Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214
[TBL] [Abstract][Full Text] [Related]
10. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
[TBL] [Abstract][Full Text] [Related]
11. [Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Risk management and traceability].
Klug B; Reinhardt J; Schröder C
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):58-62. PubMed ID: 19949763
[TBL] [Abstract][Full Text] [Related]
12. Legal basis of the Advanced Therapies Regulation.
Jekerle V; Schröder C; Pedone E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):4-8. PubMed ID: 19940965
[TBL] [Abstract][Full Text] [Related]
13. [Approval of clinical trials of immunobiological medicinal products at the Paul Ehrlich Institute].
Krafft H; Cichutek K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):168-72. PubMed ID: 15726457
[TBL] [Abstract][Full Text] [Related]
14. The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.
Carr M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):20-3. PubMed ID: 20101799
[TBL] [Abstract][Full Text] [Related]
15. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products.
Lucas-Samuel S; Ferry N; Trouvin JH
Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213
[TBL] [Abstract][Full Text] [Related]
16. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
Kroes BH
J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
[TBL] [Abstract][Full Text] [Related]
17. [The Innovation Office of the Paul-Ehrlich-Institut. Regulatory support during the scientific development of ATMP].
Ziegele B; Dahl L; Müller AT
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):857-66. PubMed ID: 21698540
[TBL] [Abstract][Full Text] [Related]
18. Regulatory landscape for cell therapy--EU view.
McBlane JW
Biologicals; 2015 Sep; 43(5):433-6. PubMed ID: 25997566
[TBL] [Abstract][Full Text] [Related]
19. [Quality requirements governing non-commercial clinical trials within the framework of clinical drug development in humans in the EU. Challenges, opportunities, and questions experienced by treatment centres].
Boos J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):196-203. PubMed ID: 15726461
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
